Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Rameda reports 37% year-over-year increase in 4Q23 revenue to EGP 534m

The company’s revenues rose by 37% year-over-year to EGP 534m in 4Q23, fueled by robust growth across all Rameda’s sectors.
21.03.24 | Source: Daily News Egypt

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda), a prominent Egyptian pharmaceutical company, disclosed its consolidated financial outcomes for the quarter concluding on 31 December 2023.

The company’s revenues rose by 37% year-over-year to EGP 534m in 4Q23, fueled by robust growth across all Rameda’s sectors. The private sales division led the surge with a 51% increase, followed by a 28% rise in domestic tender sales. For the full year, Rameda’s revenues climbed by 30% to EGP 1,922.4m, thanks to strong sales from the company’s top ten products.

Gross profit for the group surged by 41% year-over-year to EGP 254.1m in 4Q23, with a margin improvement of 1.3 % to 47.6%, demonstrating the benefits of operational efficiency. However, despite a 26% annual growth in gross profit to EGP 905.9m, the full-year margin slightly decreased by 1.4 % to 47.1% in FY23. This was attributed to a 36% hike in raw material costs, a 67% uptick in spare parts, maintenance, and materials, and a 72% rise in impairment costs totaling EGP 34.0m, including a one-time charge of EGP 25.7m related to the COVID-19 antiviral product line.

EBITDA experienced a 58% year-over-year growth to EGP 140.7m in 4Q23, with a margin increase of 3.5 % to 26.3%, thanks to effective portfolio repricing and cost-saving measures. Over the full year, EBITDA went up by 26% to EGP 532.9m, although the margin slightly contracted by 0.8 % due to a lower gross profit margin. Nevertheless, the impact was less pronounced as cost optimization efforts led to a reduction in SG&A expenses from 24% of revenues in FY22 to 23% in FY23.

Core Net Income, defined as net income before minority interest and adjusted for foreign exchange fluctuations, one-time impairments, and non-cash ESOP charges, grew by 47% year-over-year to EGP 61.6m in 4Q23, with a margin increase of 0.8 % to 11.5%. For the entire year, core net income rose by 13% to EGP 270.5m, but the margin narrowed by 2.0 % to 14.1% in FY23.

“Despite significant challenges in 2023, such as escalating inflation, supply chain issues, and foreign exchange constraints affecting raw material supplies, Rameda has achieved impressive revenue growth across all business segments,” stated Amr Morsy, CEO of Rameda.